Global Gene Editing Partnering Analysis Report 2023: Terms and Agreements for 400+ Deals Signed Since 2010 by the World's Leading Healthcare Companies
09 mars 2023 05h19 HE
|
Research and Markets
Dublin, March 09, 2023 (GLOBE NEWSWIRE) -- The "Global Gene Editing Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering.The Global Gene Editing...
India Gene Editing Technology Market Databook Report 2023-2027: CRISPR, Meganucleases, TALEN, and ZFN Products, Delivery Method, Disease/Disorders, and Applications
03 mars 2023 06h58 HE
|
Research and Markets
Dublin, March 03, 2023 (GLOBE NEWSWIRE) -- The "India Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
02 mars 2023 07h00 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Global Pharmacogenomics Market Report 2022: A $10.5 Billion Market by 2030 - Key Players are Extensively Involved in Seeking Approvals and Product Launches to Remain Competitive
28 févr. 2023 07h53 HE
|
Research and Markets
Dublin, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Pharmacogenomics Market Growth Analysis by Service, Technology, Application, End-user - Industry Revenue Estimation and Demand Forecast to 2030"...
China Gene Editing Technology Market Databook Report 2023: Business and Investment Opportunities to 2027
27 févr. 2023 10h33 HE
|
Research and Markets
Dublin, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The "China Gene Editing Technology Business and Investment Opportunities Databook - Q1 2023 Update" report has been added to ResearchAndMarkets.com's...
Global Gene Editing Technology Market Report 2023 Featuring bluebird, Beam, Caribou Bio, Cellectis, Allogene, Intellia TX, Editas Medicine, Verve, AstraZeneca, Merck, & Thermo Fisher Scientific
21 févr. 2023 11h43 HE
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Global Gene Editing Technology Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial...
Gene Therapy Global Market Report 2023: Increasing Prevalence of Cancer Fuels Demand
16 févr. 2023 08h53 HE
|
Research and Markets
Dublin, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The "Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type...
Advances in Gene Editing Technologies in Healthcare, 2023 Research Report - Next-Generation Genome Editing Tools and Improved Delivery Are Bolstering Gene Editing Therapeutics and Diagnostics
10 févr. 2023 10h53 HE
|
Research and Markets
Dublin, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The "Advances in Gene Editing Technologies in Healthcare" report has been added to ResearchAndMarkets.com's offering. CRISPR, ZFNs, and TALENs are...
CRISPR Technology Global Markets Report 2023: A $9.2 Billion Market by 2027, from $3.3 Billion in 2022
25 janv. 2023 04h08 HE
|
Research and Markets
Dublin, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The current report provides detailed exposure to the...
Eascra Biotech Selected as Finalist for 2023 SXSW Pitch
18 janv. 2023 10h14 HE
|
Eascra Biotech
BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Eascra Biotech, a new start-up building the next generation of therapeutic nanotechnologies, was selected as a finalist in the “Innovative World...